ConductScience.org, home

Paper7543822

In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.

Pietersz GA and 6 others. Cancer Immunol Immunother, 1995. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody. Papers, record 7543822. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7543822

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
1995
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
0.7
iCite
Revised in PubMed
2024-04-26
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pietersz GAG A
2Wenjun LL
3Sutton VRV R
4Burgess JJ
5McKenzie IFI F
6Zola HH
7Trapani JAJ A

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antigens, CDMajor topic
Antigens, Differentiation, B-LymphocyteMajor topic
B-LymphocytesMajor topic
Animals
Antigen-Antibody Reactions
Antigens, CD19
Humans
Idarubicin
Immunity, Cellular
Immunoconjugates
Mice
Mice, SCID
Recombinant Fusion Proteins
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130693Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.Immunochemistry1978https://conductscience.org/library/papers/30693PubMed
23888313A clinical trial of anti-idiotype therapy for B cell malignancy.Blood1985https://conductscience.org/library/papers/3888313PubMed
33127726Reshaping human antibodies for therapy.Nature1988https://conductscience.org/library/papers/3127726PubMed
41568225Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal antibody E48 F(ab')2.Cancer Res1992https://conductscience.org/library/papers/1568225PubMed
57687521Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.Cancer Immunol Immunother1993https://conductscience.org/library/papers/7687521PubMed
63464004Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.Proc Natl Acad Sci U S A1986https://conductscience.org/library/papers/3464004PubMed
78306242Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies.Cancer1994https://conductscience.org/library/papers/8306242PubMed
88099991Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.Lancet1993https://conductscience.org/library/papers/8099991PubMed
92161448Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer.J Clin Oncol1990https://conductscience.org/library/papers/2161448PubMed
108428365Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.Cancer Res1993https://conductscience.org/library/papers/8428365PubMed
114016762Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients.Cancer Res1985https://conductscience.org/library/papers/4016762PubMed
122904526Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.Lancet1988https://conductscience.org/library/papers/2904526PubMed
131428411Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.Int J Cancer Suppl1992https://conductscience.org/library/papers/1428411PubMed
144549735Plasma cell surface antigen on human blood lymphocytes.Nature1974https://conductscience.org/library/papers/4549735PubMed
158327892Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.Science1993https://conductscience.org/library/papers/8327892PubMed
161373410Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2.Int J Cancer1992https://conductscience.org/library/papers/1373410PubMed
171638557A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a.Cancer Immunol Immunother1992https://conductscience.org/library/papers/1638557PubMed
187682986Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody.Immunology1993https://conductscience.org/library/papers/7682986PubMed
198318495Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma.J Immunother Emphasis Tumor Immunol1993https://conductscience.org/library/papers/8318495PubMed
20942051A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal Biochem1976https://conductscience.org/library/papers/942051PubMed

See all 45 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
36264086Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models.Oncotarget2022https://conductscience.org/library/papers/36264086PubMed
35755944Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus.Mol Ther Methods Clin Dev2022https://conductscience.org/library/papers/35755944PubMed
17665197Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.Cancer Immunol Immunother2008https://conductscience.org/library/papers/17665197PubMed
17495978A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.Leukemia2007https://conductscience.org/library/papers/17495978PubMed
17091246Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.Springer Semin Immunopathol2006https://conductscience.org/library/papers/17091246PubMed
16217038Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.Proc Natl Acad Sci U S A2005https://conductscience.org/library/papers/16217038PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7543822

GET https://conductscience.org/api/papers/v1/7543822/references?page=2